Richard Cross, MD
Nephrology · Saint Clair Shores, MINPI 1972771061
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $86,188 of the $96,444 with a category attached, or 89.4%. 28 manufacturers reported payments, led by AstraZeneca at 55.9% of the total. Reporting peaked in 2024 at $22,231 and has fallen 63.0% since, to $8,216 in 2025. Among nephrology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 213 payments — averaging $452.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$54K
- Lilly USA, LLC$19K
- Boehringer Ingelheim$11K
- Mallinckrodt Hospital Products Inc.$6K
- ANI Pharmaceuticals, Inc.$3K
- Covidien LP$659
- plus $3K from 22 others
What the payments were for
- Speaking & faculty fees$86,18889%
- Travel & lodging$2,7123%
- Food & beverage$7,4848%
- Education$600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 67 | $53,877 |
| Lilly USA, LLC | 21 | $18,813 |
| Boehringer Ingelheim | 16 | $10,580 |
| Mallinckrodt Hospital Products Inc. | 10 | $6,426 |
| ANI Pharmaceuticals, Inc. | 15 | $3,307 |
| Covidien LP | 7 | $659 |
| Bard Peripheral Vascular, Inc. | 10 | $445 |
| Bayer | 9 | $361 |
| Amgen(2 entities) | 11 | $304 |
| Vifor Pharma, Inc. | 8 | $265 |
| Ardelyx, Inc. | 9 | $250 |
| Calliditas Therapeutics US Inc. | 2 | $146 |
| Otsuka America Pharmaceutical, Inc. | 2 | $145 |
| Mallinckrodt Enterprises LLC | 1 | $122 |
| Recor Medical Inc | 1 | $121 |
| GSK | 1 | $121 |
| Mozarc Medical US LLC | 4 | $102 |
| Novartis | 3 | $72 |
| Cormedix Inc. | 2 | $54 |
| Travere Therapeutics, Inc. | 4 | $49 |
| Daiichi Sankyo Inc. | 2 | $38 |
| Avenu Medical Inc. | 1 | $37 |
| Medtronic | 1 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Siemens Medical Solutions USA, Inc. | 1 | $25 |
| Aurinia Pharma U.S., Inc. | 1 | $24 |
| Angiodynamics, Inc. | 1 | $19 |
| Akebia Therapeutics Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOKELMA$53,296
- JARDIANCE$29,154
- ACTHAR$6,344
- PURIFIED CORTROPHIN GEL$2,986
- Argyle$297
- Kerendia$235
- COVERA$142
- XPHOZAH 30 MG$139
- Tavneos$125
- JYNARQUE$125
- Veltassa$122
- Paradise Ultrasound Renal Denervation System$121
- BENLYSTA$121
- TARPEYO$120
How this compares
$96,444 in reported general payments places this provider in the 95th percentile of 325 nephrology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JynarqueTolvaptan | 11 | $199,885 |
| JardianceEmpagliflozin | 35 | $46,651 |
| XphozahTenapanor Hcl | 12 | $35,984 |
| FarxigaDapagliflozin Propanediol | 19 | $20,569 |
| Bumetanide | 212 | $9,292 |
| Calcitriol | 178 | $6,042 |
| Sevelamer Carbonate | 26 | $4,974 |
| Carvedilol | 177 | $2,861 |
| Nifedipine ErNifedipine | 29 | $2,590 |
| Hydralazine Hcl | 87 | $2,076 |
| Losartan Potassium | 145 | $2,020 |
| Terazosin Hcl | 39 | $2,015 |
| Potassium Chloride | 40 | $1,821 |
| Clonidine Hcl | 38 | $992 |
| Allopurinol | 63 | $736 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Jynarque | $145 | $199,88511 claims |
| Boehringer IngelheimJardiance | $10,580 | $46,65135 claims |
| AstraZenecaFarxiga | $53,877 | $20,56919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 325 nephrology providers in Michigan.
Other nephrology in Saint Clair Shores
- Faten AyyoubSaint Clair Shores$5K
- Alexander YevzlinAnn Arbor$1.1M
- Muwaffaq SalamehBay City$164K
- Laura MarianiAnn Arbor$150K
- Crystal Gardner-MartinLivonia$140K
- Katherine KwonSaint Joseph$111K
- Anatole BesarabDetroit$102K
- Kausik UmanathDetroit$85K
- Joel TopfRoseville$79K
- Matthias KretzlerAnn Arbor$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.